218 related articles for article (PubMed ID: 30135687)
41. [Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].
Qiao X; Zhang W; Li Z; Zeng Y
Zhongguo Zhong Yao Za Zhi; 2011 Mar; 36(6):806-9. PubMed ID: 21710755
[TBL] [Abstract][Full Text] [Related]
42. Antiretroviral APOBEC3 cytidine deaminases alter HIV-1 provirus integration site profiles.
Ajoge HO; Renner TM; Bélanger K; Greig M; Dankar S; Kohio HP; Coleman MD; Ndashimye E; Arts EJ; Langlois MA; Barr SD
Nat Commun; 2023 Jan; 14(1):16. PubMed ID: 36627271
[TBL] [Abstract][Full Text] [Related]
43. The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.
Sharma S; Patnaik SK; Taggart RT; Baysal BE
Sci Rep; 2016 Dec; 6():39100. PubMed ID: 27974822
[TBL] [Abstract][Full Text] [Related]
44. Association of single nucleotide polymorphisms of APOBEC3G with susceptibility to HIV-1 infection and disease progression among men engaging in homosexual activity in northern China.
Li Q; Qiao Y; Zhang G; He N; Zhang X; Jia X; Sun H; Wang C; Xu L
Arch Virol; 2017 Jan; 162(1):259-268. PubMed ID: 27730383
[TBL] [Abstract][Full Text] [Related]
45. In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models.
Nakaya Y; Stavrou S; Blouch K; Tattersall P; Ross SR
J Virol; 2016 Sep; 90(17):8005-12. PubMed ID: 27356895
[TBL] [Abstract][Full Text] [Related]
46. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
[TBL] [Abstract][Full Text] [Related]
47. Protecting APOBEC3G: a potential new target for HIV drug discovery.
Stopak K; Greene WC
Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
[TBL] [Abstract][Full Text] [Related]
48. Intracellular detection of differential APOBEC3G, TRIM5alpha, and LEDGF/p75 protein expression in peripheral blood by flow cytometry.
Mous K; Jennes W; De Roo A; Pintelon I; Kestens L; Van Ostade X
J Immunol Methods; 2011 Sep; 372(1-2):52-64. PubMed ID: 21784078
[TBL] [Abstract][Full Text] [Related]
49. APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.
Hosseini I; Mac Gabhann F
PLoS One; 2013; 8(5):e63984. PubMed ID: 23724012
[TBL] [Abstract][Full Text] [Related]
50. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
Schumacher AJ; Haché G; Macduff DA; Brown WL; Harris RS
J Virol; 2008 Mar; 82(6):2652-60. PubMed ID: 18184715
[TBL] [Abstract][Full Text] [Related]
51. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
[TBL] [Abstract][Full Text] [Related]
52. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.
Land AM; Ball TB; Luo M; Pilon R; Sandstrom P; Embree JE; Wachihi C; Kimani J; Plummer FA
J Virol; 2008 Aug; 82(16):8172-82. PubMed ID: 18550667
[TBL] [Abstract][Full Text] [Related]
53. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
[TBL] [Abstract][Full Text] [Related]
54. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
[TBL] [Abstract][Full Text] [Related]
56. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
57. Characterization of APOBEC3 variation in a population of HIV-1 infected individuals in northern South Africa.
Matume ND; Tebit DM; Gray LR; Turner SD; Rekosh D; Bessong PO; Hammarskjöld ML
BMC Med Genet; 2019 Jan; 20(1):21. PubMed ID: 30660178
[TBL] [Abstract][Full Text] [Related]
58. HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.
Lanca AM; Collares JK; Ferreira JL; Lima DM; Brigido LF; Rodrigues R; Fonseca BA
Mem Inst Oswaldo Cruz; 2012 Feb; 107(1):96-101. PubMed ID: 22310542
[TBL] [Abstract][Full Text] [Related]
59. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
[TBL] [Abstract][Full Text] [Related]
60. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.
Love RP; Xu H; Chelico L
J Biol Chem; 2012 Aug; 287(36):30812-22. PubMed ID: 22822074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
